Shutterstock
Signal detection in post-market drug monitoring has changed little in 70 years, but now that shake-up is coming in the form of advanced AI technology combined with democratised access to standardised real-world data. The result will be a rapid and widespread adoption of proactive signal detection. And not just in adverse event monitoring, but also in identifying previously untapped opportunities for drug repurposing, says ArisGlobal’s Elizabeth Smalley.